KEI Research Note 2020:2 Role of Private Sector, Governments and Charities in Funding Research and Development Related to Tocilizumab Luis Gil Abinader, May 28, 2020. From the Introduction: The funding of R&D for tocilizumab can be described as having three… Continue Reading
KEI Research Note 2020:1 Government funding related to the cobas Liat Analyzer PCR testing device. Luis Gil Abinader, April 22, 2020. Introduction Polymerase chain reaction (PCR) testing technique Automatization of the PCR testing technique SARS-Cov-2 emergency use authorizations for PCR… Continue Reading
On July 19, 2018, the U.S. District Court, Northern District of California, denied a permanent injunction requested by Illumina, Inc, and instead ruled that a forward looking royalty for continued non-voluntary use of the invention, a type of compulsory license,… Continue Reading
Bayh-Dole cases involving royalty free or march-in rights 1997 Cellpro case This was a strong case involving two competing medical devices, both invented on NIH grants, and a bad ending. The NIH rejection of the Cellpro march-in request led to… Continue Reading
On February 20, 2006, Martin Terberger, the Head of Unit for Pharmaceuticals in the European Commission Directorate-General for Enterprise and Industry, wrote to Greg Perry of the European Generic medicines Association (EGA). The letter was a follow-up to an inquiry from the EGA regarding “the question of data exclusivity under the European pharmaceutical legislation,” in cases where a government overrode the exclusive rights of a patent and granted a compulsory license, and/or in a case of a medical emergency.
Schumer’s October 16, 2005 press release As Avian Flu Closes In On U.S., Schumer Calls For Immediate Action: Demands Suspension Of Tamiflu Patent So Vaccine Can Be Mass-Produced, Dramatically Increasing Supply Tamiflu, the Only Effective Treatment of Bird Flu in… Continue Reading